Makena Active Ingredient Compounding Ban Gets US FDA Panel Nod

 
• By Sue Sutter
  
Sunset
The sun is quickly setting on compounding of HPC for preterm birth prevention. (Shutterstock)
Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

SpotifyApple PodcastsWebsite

More from US Advisory Committees

More from Pathways & Standards